Diabetes drug may also protect bones, early trial hints

NCT ID NCT06050577

Ongoing Disease control Sponsor: Odense University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing whether oral semaglutide (Rybelsus), a drug already used for type 2 diabetes, can improve bone health in people aged 50-85 with diabetes and weak bones (osteopenia). Over 52 weeks, 64 participants will receive either the drug or a placebo. Researchers will measure bone formation and breakdown markers, bone density, and bone strength to see if the drug shifts the balance toward stronger bones.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: oral semaglutide (Rybelsus)
What this could lead to: If it works, this could point toward a treatment that helps people with type 2 diabetes maintain stronger bones and reduce fracture risk.
What could go wrong: This is a small, early-phase trial with only 64 participants. The results may not apply to everyone, and the bone benefits might be too small to matter in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOPENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Bone Diseases, Metabolic type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OSTEOPENIA TYPE 2 DIABETES

Contacts and locations

Locations

Odense University Hospital

Odense, 5000, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.